IO Biotech, Inc. (IOBT)

Market Cap	54.06M
Revenue (ttm)	n/a
Net Income (ttm)	-90.34M
Shares Out	65.88M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	297,659
Open	0.860
Previous Close	0.870
Day's Range	0.800 - 0.910
52-Week Range	0.733 - 2.098
Beta	0.42
Analysts	Strong Buy
Price Target	9.33 (+1,036.97%)
Earnings Date	Nov 12, 2024

About IOBT

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2021
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: IOBT
• Website: https://www.iobiotech.com

Analyst Forecast

According to 3 analysts, the average rating for IOBT stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 1,036.97% from the latest price.

Price Target

$9.33

(1,036.97% upside)

Analyst Consensus: Strong Buy